IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Tennessee

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Tennessee $ 6,731,451.41
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
Advanced Breath Diagnostics, LLC 13C-Spirulina Gastric Emptying Breath Test ("GEBT") $ 244,479.24  
Asklepion Pharmaceuticals LLC Citrulline $ 244,479.25  
Asklepion Pharmaceuticals LLC Cholic Acid $ 72,395.14 $ 172,084.11
BioMimetic Therapeutics Inc Orthopedic Program $ 244,479.25  
BioMimetic Therapeutics Inc Sports Medicine Research and Development Program $ 244,479.25  
Cumberland Pharmaceuticals Inc Cumberland TPr Antagonist $ 13,483.50 $ 230,995.75
Cumberland Pharmaceuticals Inc. Cumberland Caldolor Pediatrics $ 57,556.50 $ 186,922.75
Cumberland Pharmaceuticals Inc. Cumberland Acetadote ALF $ 51,000.00 $ 77,229.50
Cumberland Pharmaceuticals, Inc Cumberland Acetodate EF $ 67,886.00 $ 176,593.25
ED Laboratories, Inc EDL 2000 $ 104,060.50 $ 140,418.75
EDP Biotech Corporation ColoMarker $ 244,479.25  
ExtraOrtho Inc Biopolymer Sponge   $ 244,479.25
Glenveigh Pharmaceuticals LLC Belfort-Dildy Obstetric Tamponade System (BD OTS) $ 244,479.25  
GLENVEIGH PHARMACEUTICALS, LLC DEVICE FOR MEASURING CERVICAL DILATION DURING ACTIVE LABOR $ 48,589.50 $ 32,607.50
Glenveigh Pharmaceuticals, LLC Development of Therapeutic and Diagnostic for Preeclampsia (Project DIF) $ 109,469.00 $ 46,957.50
GTx ALK Inhibition Therapy $ 244,479.24  
GTx, Inc Toremifene 20mg $ 244,479.24  
GTx, Inc. Ostarine $ 244,479.24  
GTx, Inc. GTx-758 $ 244,479.24  
GTx, Inc. Toremifene 80mg $ 244,479.24  
Hematotypes, Inc. Rapid multiparameter immunophenotyping of target cell populations $ 5,182.00 $ 3,956.00
Insight Genetics, Inc Novel Molecular Diagnostic Tests for Cancers Driven by Anaplastic Lymphoma Kinase (ALK) $ 244,479.25  
InVivoLink, LLC InVivoLink Implant Registry $ 80,621.00 $ 163,858.25
Molecular Design International, Inc. Compound 49b prevents retinopathy $ 225,000.00 $ 19,479.24
NellOne Therapeutics Inc Development of novel cardiac and skeletal muscle regenerating therapy $ 113,397.50 $ 131,081.74
Pathfinder Therapeutics, Inc Image-Guided Cancer Therapeutic Delivery System $ 244,479.25  
Provectus Pharmaceuticals, Inc. Pharmaceutical agent PV-10 $ 244,479.24  
RxBio, Inc. Rx100 $ 182,397.50 $ 62,081.75
Surgivision, Inc ClearPoint $ 244,479.25  
SURGIVISION, INC. SafeLead $ 244,479.25  
Page Last Reviewed or Updated: 04-Jun-2014